Table 1. Demographic and clinical characteristics of the sample.
| ASG N=50 | CG N=30 | p | ||
|---|---|---|---|---|
| Age (y) – mean (SD) | 43.44 (9.91) | 38.70 (8.52) | 0.032* | |
| Gender | 0.724** | |||
| M - n (%) | 40 (80.00) | 23 (76.70) | ||
| F – n (%) | 10 (20.00) | 7 (23.3) | ||
| Weight (kg) – mean (SD) | 71.89 (15.38) | 75.35 (14.30) | 0.413*** | |
| Height (m) – mean (SD) | 1.66 (0.09) | 1.68 (0.079) | 0.348* | |
| BMI | 25.20 (4.93) | 26.92 (10.01) | 0.358*** | |
| MASEI – mean (SD) | 16.32 (11.22) | 10.70 (5.27) | 0.063*** | |
| Disease duration (y) | 11.11 (6.76) | - | - | |
| Patient Global Assessment – VAS 0–10 cm | 4.46 (2.55) | - | - | |
| Physician Global Assessment – VAS 0–10 cm | 3.22 (1.91) | - | - | |
| BASDAI | 3.19 (2.10) | - | - | |
| BASFI | 4.27 (2.67) | - | - | |
| BASMI | 4.74 (2.35) | - | - | |
| HAQ-S | 0.57 (0.49) | - | - | |
| ASDAS-ESR | 2.37 (0.99) | - | - | |
| SPARCC | 2.80 (3.87) | - | - | |
| MASEI | 16.32 (11.22) | - | - | |
| ESR (mm) | 19.94 (16.57) | - | - | |
ASG: ankylosing spondylitis group; CG: control group; Y: years; M: male; F: female; BMI: body mass index; VAS: visual analog scale; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; HAQ-S: Health Assessment Questionnaire for Spondyloarthropathies; ASDAS-ESR: disease activity index developed by the Assessment of SpondyloArthritis International Society (using the ESR); SPARCC: Clinical index of peripheral enthesitis from the Spondyloarthritis Research Consortium of Canada; MASEI: Madrid Sonographic Enthesis Index; ESR: erythrocyte sedimentation rate in the first hour.
*
Student's t-test;
**
χ2 test;
***
Mann–Whitney test.